---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033144"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:38:59.742485+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LIXTE reports Roche-backed trial, new CMO, and SCLC trial termination

## Summary
- New clinical trial with Netherlands Cancer Institute, supported by Roche, testing LB-100 + atezolizumab in metastatic colorectal cancer.
- Dr. Jan Schellens appointed Chief Medical Officer effective Aug 1, 2024; 25+ years oncology drug development experience.
- Preclinical data in EMBO Reports shows LB-100 can turn immunologically 'cold' tumors 'hot', enhancing immunotherapy benefit.
- Small cell lung cancer trial at City of Hope terminated due to limited patient accrual; exploring alternative sites.

## SEC filing metadata
- accession: 0001493152-24-033144
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/0001493152-24-033144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224033144/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033144
- JSON: https://secwatch.observer/filing/0001493152-24-033144.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.